These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24938621)

  • 1. An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib.
    Magee MH; Shearn S; Shaddinger B; Fang Z; Glaser R
    Br J Clin Pharmacol; 2014 Nov; 78(5):1014-21. PubMed ID: 24938621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics and safety of darapladib in subjects with severe renal impairment.
    Magee MH; Shaddinger B; Collins D; Siddiqi S; Soffer J
    Br J Clin Pharmacol; 2015 Oct; 80(4):654-61. PubMed ID: 25953363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial.
    Hu C; Tompson D; Magee M; Chen Q; Liu YM; Zhu W; Zhao H; Gross AS; Liu Y
    PLoS One; 2015; 10(10):e0139862. PubMed ID: 26465780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition and metabolism of darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in humans.
    Dave M; Nash M; Young GC; Ellens H; Magee MH; Roberts AD; Taylor MA; Greenhill RW; Boyle GW
    Drug Metab Dispos; 2014 Mar; 42(3):415-30. PubMed ID: 24378325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in diabetic macular edema: a 3-month placebo-controlled study.
    Staurenghi G; Ye L; Magee MH; Danis RP; Wurzelmann J; Adamson P; McLaughlin MM;
    Ophthalmology; 2015 May; 122(5):990-6. PubMed ID: 25749297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe.
    Daida H; Iwase T; Yagi S; Ando H; Nakajima H
    Circ J; 2013; 77(6):1518-25. PubMed ID: 23439604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
    Kropeit D; McCormick D; Erb-Zohar K; Moiseev VS; Kobalava ZD; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
    Br J Clin Pharmacol; 2017 Dec; 83(12):2678-2686. PubMed ID: 28722153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Darapladib for preventing ischemic events in stable coronary heart disease.
    ; White HD; Held C; Stewart R; Tarka E; Brown R; Davies RY; Budaj A; Harrington RA; Steg PG; Ardissino D; Armstrong PW; Avezum A; Aylward PE; Bryce A; Chen H; Chen MF; Corbalan R; Dalby AJ; Danchin N; De Winter RJ; Denchev S; Diaz R; Elisaf M; Flather MD; Goudev AR; Granger CB; Grinfeld L; Hochman JS; Husted S; Kim HS; Koenig W; Linhart A; Lonn E; López-Sendón J; Manolis AJ; Mohler ER; Nicolau JC; Pais P; Parkhomenko A; Pedersen TR; Pella D; Ramos-Corrales MA; Ruda M; Sereg M; Siddique S; Sinnaeve P; Smith P; Sritara P; Swart HP; Sy RG; Teramoto T; Tse HF; Watson D; Weaver WD; Weiss R; Viigimaa M; Vinereanu D; Zhu J; Cannon CP; Wallentin L
    N Engl J Med; 2014 May; 370(18):1702-11. PubMed ID: 24678955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
    Yeo A; Li L; Warren L; Aponte J; Fraser D; King K; Johansson K; Barnes A; MacPhee C; Davies R; Chissoe S; Tarka E; O'Donoghue ML; White HD; Wallentin L; Waterworth D
    PLoS One; 2017; 12(7):e0182115. PubMed ID: 28753643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
    Zhao Q; Iyer GR; Verhaeghe T; Truyen L
    J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of linagliptin in subjects with hepatic impairment.
    Graefe-Mody U; Rose P; Retlich S; Ring A; Waldhauser L; Cinca R; Woerle HJ
    Br J Clin Pharmacol; 2012 Jul; 74(1):75-85. PubMed ID: 22242621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
    Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.
    Halabi A; Maatouk H; Siegler KE; Faisst N; Hinrichsen H
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):290-6. PubMed ID: 27128835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
    Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
    Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.
    Lawendy N; Lamba M; Chan G; Wang R; Alvey CW; Krishnaswami S
    Clin Pharmacol Drug Dev; 2014 Nov; 3(6):421-7. PubMed ID: 27129117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
    Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
    Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
    Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
    Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
    Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
    Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.